| Name | Altretamine |
| Description | Altretamine (ENT-50852) is an alkylating agent with antineoplastic activity. |
| In vitro | In elevated plus-maze and light/dark tests in BALB/c mice, Flumazenil (1 mg/kg) exhibited strong anxiolytic effects. Flumazenil (3 mg/kg) prevented alterations induced by chronic ethanol withdrawal in mice, such as decreased open arm time and percentage of open arm entries. In rats, Flumazenil (10 mg/kg) effectively counteracted the reductive effects of tetrahydropregnanolone. Flumazenil (5-20 mg/kg) antagonized the effects of diazepam in mice without affecting the anticonvulsant and adverse responses to GYKI52466. In the MES model, as opposed to the PTZ test, Flumazenil slightly reduced the anticonvulsant activity of NBQX. Flumazenil binds to central benzodiazepine (BZD) receptors, thereby antagonizing or reversing the neurophysiological effects of BZD depressants and agonists. It reverses the depressant sedative responses caused by the combined use of BZD and other drugs but is not effective for cyclic antidepressant overdose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.9 mg/mL (32.81 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 0.5 mg/mL (2.38 mM), Sonication is recommended.
Ethanol : 8 mg/mL (38.04 mM), Sonication is recommended.
|
| Keywords | WR95704 | WR 95704 | RB1515 | RB 1515 | NSC-13875 | NSC 13875 | Inhibitor | inhibit | ENT50852 | ENT 50852 | DNAAlkylator | DNAAlkylation | DNA Alkylator/Crosslinker | DNA Alkylator | DNA Alkylation | DNA Alkylating | Crosslinker | Altretamine |
| Inhibitors Related | Cyclophosphamide hydrate | Streptozotocin | Busulfan | ATMP | N-Nitroso-N-methylurea | Tectoquinone | 2-Iodoacetamide | Cyclophosphamide | Methyl methanesulfonate | Temozolomide | Cisplatin | Carmustine |
| Related Compound Libraries | Pesticide Compound Library | Target-Focused Phenotypic Screening Library | Approved Drug Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | NMPA-Approved Drug Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
